Notes: Inaxaplin is an apolipoprotein L1 (ApoL1) inhibitor.{69966} It inhibits cytotoxicity induced by overexpression of the APOL1 variants G1 and G2 in cells when used at a concentration of 3 µM. Inaxaplin also reduces ApoL1 G1-induced inhibition of global protein synthesis in podocytes isolated from APOL1 transgenic mice. In vivo, inaxaplin (10 mg/kg) reduces podocyte injury and proteinuria in APOL1 transgenic mice.